An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.
The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.
According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.
We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).
View original post 465 more words